Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments

by dyadic | Nov 12, 2026 | Press Releases

Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation Dyadic to host earnings call on November 12, 2026, at 5:00 p.m. ET JUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc....

Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations

by dyadic | Nov 12, 2026 | Press Releases

Preclinical Studies Will Compare C1-Produced Antibodies to Their CHO-Produced CounterpartsJUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), operating as Dyadic Applied...

Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.

by dyadic | Nov 10, 2026 | Press Releases

JUPITER, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Corp. today announced a strategic collaboration aimed at advancing the...

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026

by dyadic | Oct 30, 2026 | Press Releases

JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology...

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

by dyadic | Aug 13, 2026 | Press Releases

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and...